Trials / Terminated
TerminatedNCT05787496
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- NextCure, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Chronic Myelomonocytic Leukemia
- Relapsed or Refractory Myelodysplastic Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NC525 | Monoclonal antibody specific for LAIR-1 |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
- First posted
- 2023-03-28
- Last updated
- 2026-01-28
- Results posted
- 2026-01-28
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05787496. Inclusion in this directory is not an endorsement.